Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.33 AUD | -2.26% | -1.81% | -10.17% |
04-30 | ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8% | MT |
04-17 | Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant | MT |
Valuation
Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 139.8 | 370.5 | 447.6 | - | - |
Enterprise Value (EV) 1 | 114.4 | 349.8 | 464.7 | 470.3 | 446.9 |
P/E ratio | 11.3 x | 23.2 x | 23.6 x | 14.7 x | 13.3 x |
Yield | 1.67% | 2.17% | 2.37% | 3.17% | 3.46% |
Capitalization / Revenue | 0.79 x | 1.63 x | 1.51 x | 1.12 x | 1.02 x |
EV / Revenue | 0.65 x | 1.54 x | 1.57 x | 1.18 x | 1.02 x |
EV / EBITDA | 5.18 x | 12.6 x | 11.7 x | 8.51 x | 7.36 x |
EV / FCF | 12.4 x | 66.5 x | -109 x | 24.8 x | 19.7 x |
FCF Yield | 8.04% | 1.5% | -0.91% | 4.04% | 5.07% |
Price to Book | 2.2 x | - | 6.97 x | 5.6 x | 4.6 x |
Nbr of stocks (in thousands) | 86,286 | 86,366 | 103,380 | - | - |
Reference price 2 | 1.620 | 4.290 | 4.330 | 4.330 | 4.330 |
Announcement Date | 29/08/22 | 24/08/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | 118.1 | 176.8 | 226.9 | 296.3 | 398.3 | 437.6 |
EBITDA 1 | - | 22.1 | 27.7 | 39.81 | 55.27 | 60.68 |
EBIT 1 | - | 18.5 | 23.4 | 33.64 | 46.71 | 51.52 |
Operating Margin | - | 10.46% | 10.31% | 11.35% | 11.73% | 11.77% |
Earnings before Tax (EBT) | - | 16.08 | 23.2 | - | 43.71 | 48.32 |
Net income 1 | - | 11.12 | 16.08 | 21.32 | 30.53 | 33.77 |
Net margin | - | 6.29% | 7.09% | 7.19% | 7.66% | 7.72% |
EPS 2 | - | 0.1430 | 0.1850 | 0.1834 | 0.2945 | 0.3261 |
Free Cash Flow 1 | - | 9.196 | 5.263 | -4.25 | 19 | 22.65 |
FCF margin | - | 5.2% | 2.32% | -1.43% | 4.77% | 5.18% |
FCF Conversion (EBITDA) | - | 41.61% | 19% | - | 34.38% | 37.32% |
FCF Conversion (Net income) | - | 82.74% | 32.74% | - | 62.23% | 67.07% |
Dividend per Share 2 | - | 0.0270 | 0.0930 | 0.1027 | 0.1373 | 0.1500 |
Announcement Date | 15/12/21 | 29/08/22 | 24/08/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
---|---|---|---|---|
Net sales 1 | 81.74 | 95.04 | 110.9 | 116 |
EBITDA 1 | 10.4 | 11.7 | 13.4 | 14.3 |
EBIT 1 | 8.6 | 9.9 | 11.5 | 11.9 |
Operating Margin | 10.52% | 10.42% | 10.37% | 10.26% |
Earnings before Tax (EBT) | - | - | - | - |
Net income | 4.759 | 6.356 | 8.022 | - |
Net margin | 5.82% | 6.69% | 7.24% | - |
EPS | - | - | - | - |
Dividend per Share 2 | - | - | - | 0.0470 |
Announcement Date | 27/02/22 | 29/08/22 | 23/02/23 | 24/08/23 |
Balance Sheet Analysis
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 17 | 22.7 | - |
Net Cash position 1 | - | 25.4 | 20.8 | - | - | 0.74 |
Leverage (Debt/EBITDA) | - | - | - | 0.428 x | 0.4098 x | - |
Free Cash Flow 1 | - | 9.2 | 5.26 | -4.25 | 19 | 22.7 |
ROE (net income / shareholders' equity) | - | 21.7% | 23.6% | 18.7% | 19.1% | 19% |
ROA (Net income/ Total Assets) | - | 10.5% | 12.2% | 11.4% | 11% | 10.9% |
Assets 1 | - | 105.8 | 132.2 | 187.4 | 277.6 | 309.2 |
Book Value Per Share 2 | - | 0.7400 | - | 0.6200 | 0.7700 | 0.9400 |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | 2 | 2.16 | 2.79 | 4.85 | 4.72 |
Capex / Sales | - | 1.13% | 0.95% | 0.94% | 1.22% | 1.08% |
Announcement Date | 15/12/21 | 29/08/22 | 24/08/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.17% | 299M | |
+6.42% | 9.41B | |
+10.42% | 8.85B | |
+20.79% | 7.71B | |
+8.82% | 1.33B | |
+74.72% | 735M | |
+237.60% | 702M | |
+80.56% | 662M | |
-7.81% | 658M | |
-3.05% | 595M |
- Stock Market
- Equities
- IPG Stock
- Financials IPD Group Limited